Abstract 5394
Background
Kinase fusions (KF), such as those involving ALK, are eminently targetable genomic alterations (GA) in lung and other cancers, the latter suggested by early clinical evidence (PMID: 29079636). We undertook a review of 7260 patient samples from a tertiary cancer care-focused network of five hospitals assayed with comprehensive genomic profiling (CGP).
Methods
Hybrid capture based CGP was performed on 7260 advanced cancer cases (12/2012-2/2018), with assessment of at least 186 genes (intronic baiting for at least 14) in tissue, and 62 genes (intronic baiting for 6) in circulating tumor DNA samples. Tumor mutational burden (TMB) was determined up to 1.2 Mbp of sequenced DNA.
Results
77/7260 (1%) samples in this series harbored KF. Patients (pts) with KF+ tumors had a median age of 53 years vs. 56 years in the overall population. The TMB in KF+ cases was 3.51 mut/Mb vs. 4.39 mut/Mb for all cases. KF were found in 55 lung (71%) and 22 (29%) non-lung samples. Of KF+ cases, 71% were non-small cell lung cancer, and the remainder were sarcoma (5%), breast cancer (4%), thyroid (4%), cancer of unknown primary (4%), pancreatic (3%), colorectal (3%) and others (1% each). Of KF+ non-lung cases, 39% had BRAF fusions, 30% had ALK fusions, 26% had RET fusions, and 4% had ROS1 fusions. One KF+ sarcoma pt received matched targeted therapy with ALK inhibitors including ceritinib and crizotinib. More recently, in 2017 samples alone, 42% (10/24) of KF+ cases were non-lung.
Conclusions
Greater access to CGP has led to increased detection of advanced cancer patients with tumors harboring KF, particularly those with non-lung cancers. The low frequency of the latter is a challenge for clinical investigation. As such, innovative solutions such as basket trial for kinase inhibitors are needed, which may be feasible in an integrated cancer care system with high patient volume.
Clinical trial identification
Legal entity responsible for the study
Ankur Parikh.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
A. Parikh: Consultant: Foundation Medicine, Inc (FMI). S.M. Ali, A.B. Schrock, P. Reddy, V.A. Miller, J.S. Ross: Employee and equity interest: FMI. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract